

## Bundled Payments for Care Improvement (BPCI) Advanced Annual Check-in Questionnaire

[illegible]

1

7

### Purpose:

Participants' activities and barriers related to designing and implementing the BPCI Advanced Model



### Instructions:

The first part of the study was a pilot study. The purpose of the pilot study was to determine the feasibility of the study and to estimate the sample size required for the main study. The pilot study was conducted with 10 participants. The results of the pilot study showed that the study was feasible and that the sample size required for the main study was 100 participants.

The main study was conducted with 100 participants. The participants were recruited from a variety of sources, including social media, community organizations, and university databases. The participants were randomly assigned to two groups: the experimental group and the control group. The experimental group received the intervention, while the control group did not receive the intervention.

The intervention was a 12-week program that focused on improving the participants' understanding of the risks and benefits of the intervention. The intervention was delivered through a series of workshops and group discussions. The control group received no intervention.

The primary outcome of the study was the change in the participants' understanding of the risks and benefits of the intervention. The secondary outcomes were the participants' attitudes towards the intervention and their willingness to participate in the intervention.

The results of the study showed that the intervention significantly improved the participants' understanding of the risks and benefits of the intervention. The participants in the experimental group also had more positive attitudes towards the intervention and were more willing to participate in the intervention than the participants in the control group.

The study has several limitations. First, the study was a pilot study and therefore the results may not be generalizable to a larger population. Second, the study was conducted with a convenience sample of participants, which may limit the generalizability of the results. Third, the study did not include a blinding procedure, which may have influenced the results.

Despite these limitations, the study provides valuable information about the feasibility of the intervention and the potential for improving the participants' understanding of the risks and benefits of the intervention.

Diagram illustrating the location of the *rDNA* and *rD* genes on the *E. coli* chromosome. The *rDNA* gene is located at approximately 100 minutes, and the *rD* gene is located at approximately 110 minutes. The *rDNA* gene is transcribed into rRNA, and the *rD* gene is transcribed into 16S and 23S rRNA.

- 

D R d d R d r D R d r

- 
- 

“Open with”

- 

dr d r

**Contact:**[illegible]

1001

5000

□ □ □ □

1

□ □ □ □

□ □ □ □ □

□ □ □ □ □

100

□ □ □

9

111

1001

□ r □ □ □ □ □ D □ □ □ □ r □ □ □

☐

☐

☐

□ □ □ □ □ □ □ □ □ □ □ □ □ □

**D** **r** **d** **d** **R**

☐  
☐  
☐  
☐  
☐

[illegible]

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □

## CEHRT Use

1. *To meet this criterion, at least 75 percent of eligible clinicians in each participating APM Entity group, or each hospital if hospitals are the APM Entities, to use CEHRT to document and communicate clinical care.*

100



[illegible]

□ □ □

1.  $\frac{1}{2} \frac{d}{dt} \left( \frac{1}{2} m v^2 \right) = \frac{1}{2} m v \frac{dv}{dt}$   
 $\frac{1}{2} m v \frac{dv}{dt} = \frac{1}{2} m v \frac{dv}{dt}$

□ □ □ □ □ □ □ □ □ □ □ □ □

## Partner Agreements

1. **Definition:** A **Decision Tree** is a model for classification and regression tasks. It consists of a root node, internal nodes, and leaf nodes. The root node splits the data into two or more subsets based on a feature and a threshold. This process is repeated recursively for each subset, creating a tree structure. The leaf nodes represent the final classification or regression result.

□ □ □ □ □



☐ ☐ ☐ ☐ ☐

□ □ □ □ □

[illegible]

- ## Financial / Programmatic Infrastructure

□ □ □

1000

1000

- □ □ □ □

□ □ □ □ □ □ □ □ □ □ □ □ □

114

[illegible]

☐  
☐  
☐  
☐  
☐



□□□□ □□□□ d □□ r □□□□□□□□ d r □□□□□□□□□□ r □ d the Participant's d □□□□□□□□□□  
□ □□□□□□□□□□□□□□□ r □□ r □□ rd □□□□□□□□□□□□□□□□ rr □□□□ □□□□□□

### Internal Cost Savings (ICS)

[illegible]

☐ If selected 'Yes' to question 1, has the Participant \_\_\_\_\_d \_\_\_\_\_r \_\_\_\_\_d  
\_\_\_\_\_r \_\_\_\_\_r \_\_\_\_\_d \_\_\_\_\_d \_\_\_\_\_d

### Net Payment Reconciliation Amount (NPRA)

**D** **r** **R** **d** **d** **r**

**r** **r** **d** **d** [Performance Period 1: October 1, 2018 through June 30, 2019]



[illegible]

□ □ □

[illegible]

☐

☐

☐

[illegible]

-  

[illegible]

1001

[illegible]

333

[illegible]

□ □ □ □ □

[illegible]

☐  
☐  
☐  
☐  
☐  
☐

[illegible]

-   
  


11111111

[illegible]

□ □ □

[illegible]

word

[illegible]

□r□□□□□□r□□ □□□□r□□□□□□ □□□□□□□□ □□□□ □□□r□□□d□□□□□□

11 of 11

□ □ □

☐ If selected 'Other' to question

□ □ □ □ □ □ □ □ □ □ □ □ □ □ □



□ □ □ □ □

9

□ □ □ □

[illegible]

101

☐



[illegible][illegible]

1



1

5



## BPCI Advanced Impact









☐ If selected 'Yes' to either question 1 or 2, ☐ **d** ☐ **r** ☐

☐

□ □

1

1

1

☐☐☐ ☐

10



[illegible][illegible]

5







5

[illegible]

d

□ □ □ □ □ □ □ r □ □

					R					
--	--	--	--	--	---	--	--	--	--	--

☐ ☒ ☐ r ☐

[illegible]

## Document Submission



9

$\frac{d}{dt} \left( \frac{1}{r^2} \right) = -\frac{2}{r^3} \frac{dr}{dt}$



9

9

9

☐

9

☐☐

[illegible]

- ☐

☐

☐

☐

☐

## Self-disclosed Investigations or Sanctions




[illegible]

- ☐ ☐ ☐

2. I selected 'Yes' to participate in the study.
- I understand that my participation in the study is voluntary and that I may withdraw at any time without penalty or loss of benefits to which I am entitled. My participation in the study will be confidential, and my identity will be protected. I understand that the information I provide will be used for research purposes only and will not be shared with anyone outside the research team. I also understand that I will receive no direct benefit from participating in the study, but I may contribute to the knowledge of the field and potentially help others in the future.
- Additional information is located under Article 13 of the [Participation Agreement](#).

- ☐ ☐ ☐ ☐ ☐ ☐

### Other Issues Not Previously Listed

- 